ENTERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.7 USD | +2.66% |
|
+5.06% | -35.71% |
| May. 20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
| May. 17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27.69 | 29.5 | 18 | 5.082 | 2.835 | 6.683 | - | - |
| Enterprise Value (EV) 1 | 27.69 | 29.5 | 18 | 5.082 | 2.835 | 6.683 | 6.683 | 6.683 |
| P/E ratio | -1.53 x | -0.84 x | -0.15 x | -0.29 x | -0.09 x | -2.39 x | -1.78 x | -1.55 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 0.63 | 0.72 | 2.97 | 41.5 | 675 | 2,475 | - | - |
| Reference price 2 | 43,680 | 40,740 | 6,069 | 122.6 | 4.200 | 2.700 | 2.700 | 2.700 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/20/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.74 | -26.43 | -59.06 | -12.68 | -15.77 | -25.24 | -32.12 | -42.27 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.18 | -32.67 | -58.54 | -14.63 | -15.79 | -25.37 | -32.12 | -42.27 |
| Net income 1 | -15.18 | -41.73 | -84.52 | -14.63 | -16.1 | -10.51 | -32.12 | -42.27 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -28,560 | -48,300 | -39,774 | -420.0 | -47.88 | -1.130 | -1.520 | -1.740 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/20/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.17 | -9.382 | -5.406 | 4.39 | -2.28 | -4.062 | -4.182 | -3.433 | -4.094 | -9.226 | -3.88 | -5.183 | -6.951 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.17 | -9.627 | -5.408 | 4.391 | -3.986 | -4.071 | -4.189 | -3.434 | -4.101 | -9.292 | -3.88 | -5.183 | -6.951 |
| Net income 1 | -11.29 | -10.31 | -5.553 | 4.234 | -3.986 | -4.158 | -4.284 | -3.483 | -4.178 | 5.501 | -3.88 | -5.183 | -6.951 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 714.0 | -2,772 | -1,050 | 364.0 | -189.4 | -36.40 | -37.80 | -9.200 | -44.71 | 0.3800 | -1.550 | -0.3200 | -0.4100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/23/22 | 8/15/22 | 11/14/22 | 3/20/23 | 5/12/23 | 8/14/23 | 11/13/23 | 3/29/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/20/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.7
USD
Average target price
36
USD
Spread / Average Target
+1,233.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.71% | 6.21M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- ENTO Stock
- Financials Entero Therapeutics, Inc.
